Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo to Discuss Handling of Regenerative Medicine Products Under Health Insurance Programs
October 9, 2014
- MHLW to Add Page to Website in FY2016 to Help Hospitals, Pharmacies Select Generic Drug Makers
October 8, 2014
- Minister Calls on Hospitals, Pharmacies to Report Price Settlement Rates within October
October 8, 2014
- Editor’s Pick: Five Healthcare News Headlines for Sept. 22 - Oct. 3
October 6, 2014
- MEXT Redefines Objective of Generic Promotion Subsidy Project to Continue Funding in FY2015
October 6, 2014
- MHLW Panel Agrees that Legal Regulation of Clinical Research Would Be “Difficult”
October 3, 2014
- Govt Panel Calls for Fact-Finding Study for Annual NHI Price Revision
October 3, 2014
- MHLW Issues Guidelines on Package Insert Updates Mandated under Revised PAL
October 2, 2014
- MHLW Issues Warning on ARB, ACE Inhibitors in Pregnant Women
October 1, 2014
- PMDA Evaluating Xtandi for Risk of Thrombocytopenia
September 30, 2014
- MHLW OKs 19 Products Including MSD’s Insomnia Drug Suvorexant
September 29, 2014
- Daclatasvir/Asunaprevir Combination Therapy for Hepatitis C Now Eligible for Medical Subsidy: MHLW
September 26, 2014
- Govt Panel Approves Plan for Special Zone in Kansai Area Where Mixed-Healthcare Using Unapproved Drugs Will Be Permitted
September 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for September 8 – September 19
September 25, 2014
- Copayment Hike for New Drugs Up for Discussion towards Healthcare Overhaul
September 25, 2014
- MHLW Approves Additional Indications for Aricept, 2 Other Drugs
September 22, 2014
- MHLW Guidelines to Call for Thorough Internal Communications at Pharmas after Novartis’ Delayed ADR Reporting
September 19, 2014
- MHLW Official Concerned about Generic Codevelopment, but Denies Plans to Press for Industry Consolidation
September 19, 2014
- Selexipag, 4 Other APIs Designated as Orphan Drugs
September 19, 2014
- MHLW Launches Discussions on Requirements for Legally Backed Clinical Research Core Hospitals
September 17, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…